Cargando…

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH

Recent reports described a high incidence of nonalcoholic steatohepatitis (NASH) in patients with obstructive sleep apnea. Accordingly, we hypothesized that recurrent and intermittent hypoxemia plays an important role in the pathogenesis of NASH. Our objective was construction of a practical and acc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takayama, Fusako, Egashira, Toru, Kawasaki, Hiromu, Mankura, Mitsumasa, Nakamoto, Kazuo, Okada, Shigeru, Mori, Akitane
Formato:	Texto
Lenguaje:	English
Publicado:	the Society for Free Radical Research Japan 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771256/ https://www.ncbi.nlm.nih.gov/pubmed/19902025 http://dx.doi.org/10.3164/jcbn.09-29

Ejemplares similares

Beneficial Effects of Fermented Green Tea Extract in a Rat Model of Non-alcoholic Steatohepatitis
por: Nakamoto, Kazuo, et al.
Publicado: (2009)

Anti-oxidative and anti-inflammatory effects of spirulina on rat model of non-alcoholic steatohepatitis
por: Pak, Wing, et al.
Publicado: (2012)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)
por: Erhardt, A, et al.
Publicado: (2011)

A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Hadefi, Alia, et al.
Publicado: (2021)

The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)
por: Salvoza, Noel, et al.
Publicado: (2022)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis
por: Antraco, Vitor Jacó, et al.
Publicado: (2021)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
por: Galatou, Eleftheria, et al.
Publicado: (2022)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH
por: Fishman, Jesse, et al.
Publicado: (2023)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH)
por: Sookoian, Silvia, et al.
Publicado: (2016)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr (-/-) mice
por: Garcia-Jaramillo, Manuel, et al.
Publicado: (2019)

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
por: Wu, Xi-Xi, et al.
Publicado: (2021)

Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial
por: Sato, Masaya, et al.
Publicado: (2023)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
por: Okazaki, Isao, et al.
Publicado: (2014)

Correction: Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr (-/-) mice
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gq2761gbk1jtq0vt5jk3do95up